In a pharmacovigilance analysis of anti-HER2 monotherapies, trastuzumab and pertuzumab/T-DM1 (12.04%) had a higher risk of heart failure than other anti-HER2 therapies (1–2%) [22]. Here, ERBB2 is linked to heart failure.